<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128414</url>
  </required_header>
  <id_info>
    <org_study_id>DCASL30501-2</org_study_id>
    <secondary_id>EUDRACT number 2005-001570-28</secondary_id>
    <nct_id>NCT00128414</nct_id>
  </id_info>
  <brief_title>Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)</brief_title>
  <acronym>CORP</acronym>
  <official_title>Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria Locale 3, Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Sanitaria Locale 3, Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether colchicine is safe and effective in the
      treatment and prevention of recurrent pericarditis (first episode).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colchicine is safe and effective in the management of recurrent pericarditis after failure of
      conventional treatment. Preliminary data have shown that it may be effective also in
      treatment of the first attack of recurrent pericarditis and the prevention of further
      recurrences.

      Comparisons: The study will compare the safety and efficacy of colchicine in the treatment of
      the first attack of recurrent pericarditis and the secondary prevention of recurrences.
      Colchicine will be used in addition to conventional treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate at 18 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom persistence at 72 hours, remission rate at 1 week</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrences</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related hospitalization, cardiac tamponade, constrictive pericarditis within the duration of the study</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pericarditis</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients &lt;70 kg or intolerant to the highest dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine (for 6 months)</intervention_name>
    <description>colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients &lt;70 kg or intolerant to the highest dose.</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets identical in colour, shape, and taste were provided in blister packs.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the first attack of recurrent pericarditis

          -  Age≥ 18 years

          -  Informed consent

        Exclusion Criteria:

          -  Suspected neoplastic, tuberculous, or purulent etiology

          -  Known severe liver disease and/or elevated transaminases &gt;1.5 times the upper limit of
             normality

          -  Serum creatinine &gt;2.5 mg/dl

          -  Serum creatine kinase (CK) over the upper limit of normality or known myopathy

          -  Known gastrointestinal or blood disease

          -  Pregnant or lactating women or women not protected by a contraception method

          -  Known hypersensibility to colchicine

          -  Treatment with colchicine at enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita TRINCHERO, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department. Maria Vittoria Hospital. ASL 3 Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Imazio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department. Maria Vittoria Hospital. ASL3 Torino.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Imazio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department. Maria Vittoria Hospital. ASL3 Torino.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Dpt. Ospedale SS Annunziata</name>
      <address>
        <city>Savigliano</city>
        <state>CN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Dpt. Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, San Maurizio Regional Hospital</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rivoli</name>
      <address>
        <city>Rivoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Department. Maria Vittoria Hospital. ASL3 Torino</name>
      <address>
        <city>Torino</city>
        <zip>10141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Imazio M, Cecchi E, Ierna S, Trinchero R; CORP Investigators. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials--two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):830-4.</citation>
    <PMID>17885522</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>February 14, 2011</last_update_submitted>
  <last_update_submitted_qc>February 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2011</last_update_posted>
  <keyword>Pericarditis</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>Prevention</keyword>
  <keyword>Colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

